PPAR transgenic mice manifested ventricular hypertrophy, contractile dysfunction and accumulation of lipids within cardiomyocytes. In sum, the cardiac phenotype induced by PPAR over-expression mimics clinical features of human disease. To date, however, mechanisms governing the up-regulation of PPAR in diabetic heart have remained elusive.
In this issue of Circulation, Liu et al describe a novel upstream regulator of PPAR , a ubiquitin ligase named MG53 (mitsugumin 53). 7 These investigators show that this protein, also known as TRIM72, governs expression of the gene coding for PPAR . Its abundance is increased in models of diabetes, and it triggers a cascade of events that contribute to heart disease.
MG53 is a member of the so-called tripartite motif family. The protein, which is expressed exclusively in skeletal and cardiac muscle, harbors an N-terminal TRIM motif with Ring, B-box and coiled-coil moieties, and a C-terminal SPRY domain. 8 Prior work has demonstrated that MG53 plays critical roles in myogenesis, vesicle trafficking, and membrane repair. [8] [9] [10] The intrinsic E3 ligase activity of MG53 prompted researchers to identify endogenous targets. Prominent ones include the insulin receptor and IRS-1 (insulin receptor substrate-1), critical molecules in the insulin signaling cascade. 11, 12 This intimate connection between MG53
and elements of the insulin cascade suggested, in turn, that MG53 participates in metabolic regulation. Indeed, these investigators reported previously that MG53 is substantially upregulated in skeletal muscle in preclinical models of diabetes. 12 Genetic silencing of MG53
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The in in ntr tr trin in i si si sic c c E3 E3 E lig ig gas as ase e e ac ac acti ti t vi vi vity ty o o of f f MG MG MG53 53 53 p p pr r rom om mpt pt ted ed ed r r res es esea ea earc rc r he he hers rs rs t t to o o id id iden enti ti t fy fy fy e e end nd ndog o enous proved to be sufficient to activate the PPAR gene promoter in a luciferase assay, and ChIP assays suggest that the protein is recruited to the promoter. Finally, MG53 not only stimulated PPAR expression but also augmented levels of PPAR targets. Functionally, MG53-induced lipid uptake in cardiomyocytes is critically dependent on PPAR , as knockdown of PPAR strongly attenuated lipid accumulation.
As with any important study, this one raises new and interesting questions. Diabetes is typically associated with elevations in circulating glucose, free fatty acids, and various hormones and cytokines. Cardiac uptake of fatty acids is increased, which is associated with impairment of riggers pathological changes. For one, they employed RNA-seq to define global al alt lt ter erat at atio io ons ns ns i i in n he transgenic hearts, uncovering significant activation of the PPAR signaling pathway. As an m mpo po port rt rta an ant t t co co c r r rrel lat at ati iv ive observation, they note that t t M M MG G53 induction n is i a acc cc co om ompanied by up- would be a maladaptive turn of events in the cardiomyocyte.
Insulin is a major anabolic hormone. It is not surprising then that diabetes, a state of absolute or relative insulin resistance, is marked by activation of catabolic events. Indeed, as a general rule, catabolic pathways, such as the ubiquitin-proteasome system (UPS), are activated in diabetes. In this report, we learn that an element within a major catabolic cascade, the UPS, actually promotes pathogenesis of diabetic cardiomyopathy.
In the case of type 2 diabetes, however, the situation is more complex. In end-stage disease, pancreatic beta cells are depleted, and circulating insulin is low. At earlier points in disease progression, however, high levels of circulating insulin are seen, and the effects in different tissues are variable. For example, insulin resistance in type 2 diabetes increases hepatic lipid synthesis, as would be expected. Seemingly paradoxically, however, it does not suppress glucose production in liver. In muscle, glucose uptake is indeed impaired. This so-called "selective insulin resistance" 15 remains a puzzle going forward. Nevertheless, in the majority of instances, catabolic pathways are activated in diabetes, and it will be important to define the role would be a maladaptive turn of events in the cardiomyocyte.
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An E3 ligase can sometimes promote transcriptional activity independent of ligase activity. 17 Other times, they govern gene transcription via monoubiquitination, a reaction that does not target substrate for degradation. Ubiquitination can also promote the binding of a transcription factor to DNA. 18 For example, monoubiquitination of FoxO4 promotes nuclear translocation, thereby enhancing transcriptional activity; deubiquitination reverses this process. 19 Again, the actions of MG53 described here do not fit neatly into any of these categories. Looking to the future, it will be of great interest to define precise mechanisms whereby MG53 regulates expression of the gene coding for PPAR .
Multiple lines of evidence point to MG53 as an essential component of the membrane repair machinery. 8, 10 Deficiency of MG53 leads to exacerbated loss of mitochondrial membrane potential and cell death triggered by ischemia/reperfusion. 20 Moreover, MG53 constitutes a primary determinant of both ischemic preconditioning and post-conditioning triggered by prosurvival pathways. 21, 22 Heterologous expression of recombinant human MG53 confers robust cytoprotection in heart 23 , lung 24 , and skeletal muscle 25 in the settings of a variety of stress conditions. The present study, however, highlights that caution must be exercised when contemplating translational strategies to activate MG53. Perhaps an ideal therapeutic approach is does not target substrate for degradation. Ubiquitination can also promote the bin in ndi ding ng ng o o of f f a a a ranscription factor to DNA. 18 For example, monoubiquitination of FoxO4 promotes nuclear r ran an nsl sl sloc oc ocat at atio io ion, n, , the he ere re reby b enhancing transcriptional ac ac a t ti ivity; deubiqui ui iti t na ati ti tion on on reverses this process. Diabetic heart disease is a large and growing public health hazard. The report by Liu et al unveils a novel -and potentially important -mechanism of pathogenesis in this disease. Their work raises the possibility that MG53 contributes to adverse events in heart by the concerted actions of two processes: targeted degradation of elements within the insulin signaling cascade and specific up-regulation of PPAR , thereby dismantling the metabolic handling of both glucose and lipids.
As we enter the age of "diabetocardiology", studies such as this are urgently needed.
These investigators are to be congratulated for their pathbreaking mechanistic work at the leading edge of a worldwide pandemic of diabetes and heart disease.
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